ELI LILLY AND COMPANY Equity Securities without Readily Determinable Fair Value, Amount
ELI LILLY AND COMPANY (LLY) had Equity Securities without Readily Determinable Fair Value, Amount of $405.00 million as of 2019-12-31, per its 10-Q filed 2020-05-01.
Discontinued › Notes › Investments
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount · last filed 2020-05-01
- 2019-12-31: Equity Securities without Readily Determinable Fair Value, Amount $405.00M.
- 2019-09-30: Equity Securities without Readily Determinable Fair Value, Amount $427.00M.
- 2019-06-30: Equity Securities without Readily Determinable Fair Value, Amount $398.60M.
- 2019-03-31: Equity Securities without Readily Determinable Fair Value, Amount $414.60M.
| Period end | Equity Securities without Readily Determinable Fair Value, Amount |
|---|---|
| 2019-12-31 | $405.00M 10-Q · filed 2020-05-01 |
| 2019-09-30 | $427.00M 10-Q · filed 2019-10-25 |
| 2019-06-30 | $398.60M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $414.60M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $414.70M 10-Q · filed 2019-10-25 |
| 2018-09-30 | $394.70M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $392.80M 10-Q · filed 2018-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |